You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

recurrent ovarian carcinoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Not yet recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +5 more
  • Biopsy
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023

Ovarian Tumors, Recurrent Ovarian Carcinoma, Relapsed Ovarian Cancer Trial in Beijing (AK112 low dose, AK112 medium dose, AK112

Terminated
  • Ovarian Neoplasms
  • +3 more
  • AK112 low dose
  • +2 more
  • Beijing, Beijing, China
    Chinese Academy of Medical Sciences and Peking Union Medical Col
Oct 8, 2022

Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma, Recurrent Fallopian Tube Carcinoma Trial in Rochester (Biopsy,

Not yet recruiting
  • Fallopian Tube Carcinosarcoma
  • +14 more
  • Biopsy
  • +6 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jun 28, 2023

Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer Trial in Boston (Durvalumab, Tremelimumab,

Terminated
  • Recurrent Gynecological Cancer
  • +10 more
  • Boston, Massachusetts
    Martin King
Oct 4, 2022

Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Boston, Houston

Recruiting
  • Recurrent Fallopian Tube Carcinoma
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jan 12, 2023

Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma Trial in Houston (Copanlisib,

Recruiting
  • Deleterious BRCA1 Gene Mutation
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 23, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +6 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
May 17, 2022

Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Recurrent Ovarian Carcinoma Trial in Beijing (Albumin-bound paclitaxel and

Recruiting
  • Ovarian Carcinoma
  • +6 more
  • Albumin-bound paclitaxel and bevacizumab
  • Beijing, Beijing, China
    Lei Li
Mar 26, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Durvalumab
  • Tremelimumab
  • Houston, Texas
    M D Anderson Cancer Center
Jul 19, 2022

Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in

Not yet recruiting
  • Ovarian Clear Cell Adenocarcinoma
  • +14 more
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • +4 more
  • Buffalo, New York
  • +1 more
Dec 16, 2022

Ovarian Clear Cell Carcinoma Trial (Zimberelimab, Metformin Hydrochloride)

Not yet recruiting
  • Ovarian Clear Cell Carcinoma
  • (no location specified)
Feb 25, 2023

Ovarian Cancer, Recurrent Ovarian Carcinoma Trial in Shibin Al Kawm (secondary cytoreductive surgery, Chemotherapy)

Withdrawn
  • Ovarian Cancer
  • Recurrent Ovarian Carcinoma
  • Shibīn Al Kawm, Menoufia, Egypt
    Menoufia University, Faculty of medicine
Apr 9, 2022

Ovarian Cancer Recurrent Trial (Fluzopril Combined With Apatinib)

Not yet recruiting
  • Ovarian Cancer Recurrent
  • Fluzopril Combined With Apatinib
  • (no location specified)
Oct 22, 2023

BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive Trial in Columbus (other, biological, drug)

Active, not recruiting
  • BRCA1 Gene Mutation
  • +9 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Sep 16, 2022

Recurrent Endometrial Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma Trial in Aurora

Active, not recruiting
  • Recurrent Endometrial Serous Adenocarcinoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Aurora, Colorado
    University of Colorado Hospital
May 24, 2022

Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma Trial in

Recruiting
  • Malignant Ovarian Epithelial Tumor
  • +9 more
  • Akt/ERK Inhibitor ONC201
  • +2 more
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
May 10, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Completed
Has Results
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Bevacizumab
  • Irinotecan Sucrosofate
  • Chicago, Illinois
    Northwestern University
Dec 21, 2022

Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Tumor Trial in Rochester

Active, not recruiting
  • Fallopian Tube Clear Cell Adenocarcinoma
  • +22 more
  • Laboratory Biomarker Analysis
  • Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
  • Rochester, Minnesota
    Mayo Clinic
Oct 7, 2022

Participation Patterns Among Recurrent Ovarian Cancer Patients

Not yet recruiting
  • Recurrent Ovarian Cancer
    • San Francisco, California
      Power Life Sciences
    Sep 30, 2023

    BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma Trial in Buffalo, New York (biological, other, drug)

    Active, not recruiting
    Has Results
    • BRCA1 Gene Mutation
    • +5 more
    • Durvalumab
    • +3 more
    • Buffalo, New York
    • +1 more
    Jan 20, 2023

    Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma Trial in

    Recruiting
    • Fallopian Tube Carcinosarcoma
    • +28 more
    • Pegylated Liposomal Doxorubicin Hydrochloride
    • Peposertib
    • Aurora, Colorado
    • +7 more
    Sep 2, 2022

    Fallopian Tube Carcinosarcoma, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma Trial in Buffalo

    Not yet recruiting
    • Fallopian Tube Carcinosarcoma
    • +10 more
    • Bevacizumab
    • +4 more
    • Buffalo, New York
      Roswell Park Cancer Institute
    Dec 29, 2022

    Ovarian Carcinoma Trial in New Haven (Sacituzumab govitecan)

    Not yet recruiting
    • Ovarian Carcinoma
    • Sacituzumab govitecan
    • New Haven, Connecticut
      Smilow Cancer Hospital at Yale New Haven
    Aug 31, 2023

    Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer Trial in Beijing (6B11-OCIK Injection, Doxorubicin)

    Recruiting
    • Recurrent Ovarian Carcinoma
    • Platinum-resistant Ovarian Cancer
    • Beijing, China
      Peking University People's hospital
    Feb 11, 2022

    Recurrent Ovarian Cancer Trial in Pittsburgh (CPI-0209, carboplatin)

    Not yet recruiting
    • Recurrent Ovarian Cancer
    • Pittsburgh, Pennsylvania
      Magee-Womens Research Institute / UPMC Magee Womens Hospital
    Jul 3, 2023